Kharfan-Dabaja, Mohamed A. and Labopin, Myriam and Brissot, Eolia and Kroger, Nicolaus and Finke, Juergen and Ciceri, Fabio and Deconinck, Eric and Blaise, Didier and Chevallier, Patrice and Gramatzki, Martin and Ganser, Arnold and Stelljes, Matthias and Edinger, Matthias and Savani, Bipin and Ruggeri, Annalisa and Sanz, Jaime and Nagler, Arnon and Mohty, Mohamad (2021) Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 193 (3). pp. 592-601. ISSN 0007-1048, 1365-2141
Full text not available from this repository. (Request a copy)Abstract
Optimal donor choice for a second allogeneic haematopoietic cell transplant (allo-HCT) in relapsed acute myeloid leukaemia (AML) remains unknown. We compared overall survival (OS) using registry data from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) involving 455 adults who received a second allo-HCT from a human leucocyte antigen (HLA)-matched unrelated (MUD) (n = 320) or a haploidentical (n = 135) donor. Eligibility criteria required adults aged >= 18 years who received a second allo-HCT for treating AML relapse between 2005 and 2019. The primary end-point was OS. There was no statistically significant difference in the median (interquartile range) age between the groups, MUD 46 (35-58) versus haploidentical 44 (33-53) years (P = 0 center dot 07). The median OS was not different between the MUD and the haploidentical groups (10 vs. 11 months, P = 0 center dot 57). Similarly, the 2-year OS was 31% for the MUD and 29% for the haploidentical donor groups. The OS was worse if the procedure was performed with active AML [hazard ratio (HR) 1 center dot 42, 95% confidence interval (CI) 1 center dot 07-1 center dot 89; P = 0 center dot 02]. Conversely, a longer time from first allo-HCT to relapse (>13 center dot 2 months) was associated with better OS (HR 0 center dot 50, 95% CI 0 center dot 37-0 center dot 69; P < 0 center dot 0001). The results of the present analysis limit the ability to recommend one donor type over another when considering a second allo-HCT for relapsed AML. Our findings highlight that best OS is achieved when receiving the second allo-HCT in complete remission.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ; acute myeloid leukaemia; relapse; second allogeneic haematopoietic cell transplant |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) Medicine > Zentren des Universitätsklinikums Regensburg > Regensburger Centrum für Interventionelle Immunologie (RCI) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 20 Sep 2022 12:22 |
| Last Modified: | 20 Sep 2022 12:22 |
| URI: | https://pred.uni-regensburg.de/id/eprint/47667 |
Actions (login required)
 |
View Item |
